NCT06465108Phase 2Completed

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-05-23Actual

Enrollment · participants64Actual

Source updated2026-03-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-28 · 3 fields changed

Completion date type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit

− Previous value

2025-05

+ Updated value

2025-05-23

Recruitment status

Recorded edit

− Previous value

Active not recruiting

+ Updated value

Completed

Check registry source

Study details

Conditions studied

Hypoparathyroidism

Treatments or interventions studied

MBX 2109DrugAlso known as Canvuparatide

Primary outcomes · main study measures

Read the study measures

measure: To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15; description: Proportion of patients pooled across MBX 2109 doses meeting the composite criteria at week 12/Visit 15 * Independence from active vitamin D supplements * Oral elemental calcium doses of ≤600 mg/day * Serum albumin-adjusted calcium (AdjCa) values of 8.2 to 10.6 mg/dL; timeFrame: Week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history